Human Immunodeficiency Virus Type 1 Vif Functionally Interacts with Diverse APOBEC3 Cytidine Deaminases and Moves with Them between Cytoplasmic Sites of mRNA Metabolism

ABSTRACT VifIIIB, which has been a standard model for the viral infectivity factor of human immunodeficiency virus type 1 (HIV-1), binds the cytidine deaminase APOBEC3G (A3G) and induces its degradation, thereby precluding its lethal incorporation into assembling virions. Additionally, VifIIIB less efficiently degrades A3F, another potent anti-HIV-1 cytidine deaminase. Although the APOBEC3 paralogs A3A, A3B, and A3C have weaker anti-HIV-1 activities and are only partially degraded by VifIIIB, we found that VifIIIB induces their emigration from the nucleus to the cytosol and thereby causes net increases in the cytosolic concentrations and anti-HIV-1 activities of A3A and A3B. In contrast, some other Vifs, exemplified by VifHXB2 and VifELI-1, much more efficiently degrade and thereby neutralize all APOBEC3s. Studies focused mainly on A3F imply that it occurs associated with mRNA-PABP1 in translationally active polysomes and to a lesser extent in mRNA processing bodies (P-bodies). A3F appears to stabilize the P-bodies with which it is associated. A correspondingly small proportion of VifIIIB also localizes in P-bodies in an A3F-dependent manner. Stress causes A3A, A3B, A3C, and A3F to colocalize efficiently with VifIIIB and mRNA-PABP1 complexes in stress granules in a manner that is prevented by cycloheximide, an inhibitor of translational elongation. Coimmunoprecipitation studies suggest that Vifs from different HIV-1 isolates associate with all tested APOBEC3s. Thus, Vifs interact closely with structurally diverse APOBEC3s, with effects on their subcellular localization, degradation rates, and antiviral activities. Cytosolic APOBEC3-Vif complexes are predominantly bound to mRNAs that dynamically move between translationally active and storage or processing pools.

[1]  N. Landau,et al.  Analysis of Vif-induced APOBEC3G Degradation Using an α-Complementation Assay , 2007 .

[2]  M. Malim,et al.  APOBEC-mediated viral restriction: not simply editing? , 2007, Trends in biochemical sciences.

[3]  W. Greene,et al.  Newly Synthesized APOBEC3G Is Incorporated into HIV Virions, Inhibited by HIV RNA, and Subsequently Activated by RNase H , 2007, PLoS pathogens.

[4]  W. Greene,et al.  Distinct Patterns of Cytokine Regulation of APOBEC3G Expression and Activity in Primary Lymphocytes, Macrophages, and Dendritic Cells* , 2006, Journal of Biological Chemistry.

[5]  N. Landau,et al.  Analysis of Vif-induced APOBEC3G degradation using an alpha-complementation assay. , 2007, Virology.

[6]  M. Malim,et al.  Antiviral Protein APOBEC3G Localizes to Ribonucleoprotein Complexes Found in P Bodies and Stress Granules , 2006, Journal of Virology.

[7]  W. Greene,et al.  High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition , 2006, Proceedings of the National Academy of Sciences.

[8]  M. Marin,et al.  The Anti-HIV-1 Editing Enzyme APOBEC3G Binds HIV-1 RNA and Messenger RNAs That Shuttle between Polysomes and Stress Granules* , 2006, Journal of Biological Chemistry.

[9]  W. J. Esselman,et al.  Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family , 2006, Journal of Virology.

[10]  Jialing Huang,et al.  Alpha Interferon Potently Enhances the Anti-Human Immunodeficiency Virus Type 1 Activity of APOBEC3G in Resting Primary CD4 T Cells , 2006, Journal of Virology.

[11]  W. Greene,et al.  Multifaceted antiviral actions of APOBEC3 cytidine deaminases. , 2006, Trends in immunology.

[12]  T. Rana,et al.  Human Retroviral Host Restriction Factors APOBEC3G and APOBEC3F Localize to mRNA Processing Bodies , 2006, PLoS pathogens.

[13]  Xianghui Yu,et al.  Differential Requirement for Conserved Tryptophans in Human Immunodeficiency Virus Type 1 Vif for the Selective Suppression of APOBEC3G and APOBEC3F , 2006, Journal of Virology.

[14]  C. Lilley,et al.  APOBEC3A Is a Potent Inhibitor of Adeno-Associated Virus and Retrotransposons , 2006, Current Biology.

[15]  B. Cullen Role and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance Factors , 2006, Journal of Virology.

[16]  S. Wahl,et al.  Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti–HIV-1 activity , 2006, The Journal of experimental medicine.

[17]  B. Cullen,et al.  Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. , 2005, Virology.

[18]  M. Marin,et al.  Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. , 2005, AIDS research and human retroviruses.

[19]  D. Ho,et al.  Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification , 2005, PLoS pathogens.

[20]  B. Cullen,et al.  Differential Sensitivity of Murine Leukemia Virus to APOBEC3-Mediated Inhibition Is Governed by Virion Exclusion , 2005, Journal of Virology.

[21]  K. Iwai,et al.  Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C Complex Is Essential for Vif Function* , 2005, Journal of Biological Chemistry.

[22]  W. Greene,et al.  Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells , 2005, Nature.

[23]  M. Neuberger,et al.  Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities , 2005, Nucleic acids research.

[24]  M. Neuberger,et al.  Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. , 2005, Molecular biology and evolution.

[25]  M. Gonda,et al.  Conservation of amino-acid sequence motifs in lentivirus Vif proteins , 2005, Virus Genes.

[26]  R. König,et al.  APOBEC3B and APOBEC3C Are Potent Inhibitors of Simian Immunodeficiency Virus Replication* , 2004, Journal of Biological Chemistry.

[27]  Xianghui Yu,et al.  Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. , 2004, Genes & development.

[28]  M. Marin,et al.  Transcriptional Regulation of APOBEC3G, a Cytidine Deaminase That Hypermutates Human Immunodeficiency Virus* , 2004, Journal of Biological Chemistry.

[29]  M. Malim,et al.  Cytidine Deamination of Retroviral DNA by Diverse APOBEC Proteins , 2004, Current Biology.

[30]  N. Landau,et al.  Recent insights into HIV-1 Vif. , 2004, Current opinion in immunology.

[31]  B. Cullen,et al.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV‐1 and HIV‐2 Vif proteins , 2004, The EMBO journal.

[32]  M. Marin,et al.  The viral infectivity factor (Vif) of HIV-1 unveiled. , 2004, Trends in molecular medicine.

[33]  Takeshi Kurosu,et al.  Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication , 2004, Journal of Virology.

[34]  B. Strack,et al.  Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway* , 2004, Journal of Biological Chemistry.

[35]  M. Llano,et al.  Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. , 2004, Virology.

[36]  Xianghui Yu,et al.  Influence of Primate Lentiviral Vif and Proteasome Inhibitors on Human Immunodeficiency Virus Type 1 Virion Packaging of APOBEC3G , 2004, Journal of Virology.

[37]  R. Parker,et al.  Identification of Edc3p as an enhancer of mRNA decapping in Saccharomyces cerevisiae. , 2004, Genetics.

[38]  Yunkai Yu,et al.  Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex , 2003, Science.

[39]  M. Marin,et al.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation , 2003, Nature Medicine.

[40]  M. Malim,et al.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif , 2003, Nature Medicine.

[41]  W. Greene,et al.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. , 2003, Molecular cell.

[42]  Joseph P. Bielawski,et al.  Widespread Adaptive Evolution in the Human Immunodeficiency Virus Type 1 Genome , 2003, Journal of Molecular Evolution.

[43]  Hui Zhang,et al.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.

[44]  Gersende Caron,et al.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.

[45]  F. Clavel,et al.  Hypermutation of HIV-1 DNA in the Absence of the Vif Protein , 2003, Science.

[46]  Roy Parker,et al.  Decapping and Decay of Messenger RNA Occur in Cytoplasmic Processing Bodies , 2003 .

[47]  J. Wedekind,et al.  Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. , 2003, Trends in genetics : TIG.

[48]  M. Malim,et al.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.

[49]  I. Dunham,et al.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. , 2002, Genomics.

[50]  P. Rose,et al.  Adaptive Mutations in the V3 Loop of gp120 Enhance Fusogenicity of Human Immunodeficiency Virus Type 1 and Enable Use of a CCR5 Coreceptor That Lacks the Amino-Terminal Sulfated Region , 2001, Journal of Virology.

[51]  D. Kabat,et al.  Cellular and Viral Specificities of Human Immunodeficiency Virus Type 1 Vif Protein , 2000, Journal of Virology.

[52]  Navid Madani,et al.  An Endogenous Inhibitor of Human Immunodeficiency Virus in Human Lymphocytes Is Overcome by the Viral Vif Protein , 1998, Journal of Virology.

[53]  B. Chesebro,et al.  Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[54]  S. M. Stearns,et al.  Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity , 1992, Journal of virology.

[55]  B. Cullen,et al.  Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. , 1991, Science.

[56]  D. Littman,et al.  Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity , 1990, Journal of virology.

[57]  J. Sodroski,et al.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants , 1990, Journal of virology.